Literature DB >> 17637687

Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.

H Levenga1, R Woestenenk, A V Schattenberg, F Maas, J H Jansen, R Raymakers, P H M De Mulder, E van de Wiel-van Kemenade, N Schaap, T de Witte, H Dolstra.   

Abstract

Donor lymphocyte infusion (DLI) after allogeneic SCT induces complete remissions in approximately 80% of patients with relapsed CML in chronic phase, but some patients do not respond to DLI. We studied absolute numbers of dendritic cell (DC) subsets and chimerism in T cells and two subsets of blood DCs (myeloid DCs (MDCs) and plasmacytoid DCs (PDCs)) in relation to DLI-induced alloreactivity. Based on T cell and DC chimerism, we identified three groups. Four patients were completely donor chimeric in T cells and DC subsets. These patients had an early stage of relapse, and three of the four patients attained complete molecular remission (CMolR) without significant GVHD. Six patients were completely donor in T cells and mixed chimeric in DC subsets. All patients entered CMolR, but this was associated with GVHD in four and cytopenia in three patients. Five patients had mixed chimerism in T cells and complete recipient chimerism in MDC; only two patients entered CMolR. Our data suggest that the combination of donor T cells and mixed chimerism in DC subsets induces a potent graft-versus-leukemia (GVL) effect in association with GVHD. DLI in patients with an early relapse and donor chimerism in both T cells and DC subsets results in GVL reactivity without GVHD.

Entities:  

Mesh:

Year:  2007        PMID: 17637687     DOI: 10.1038/sj.bmt.1705777

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.

Authors:  Lien De Somer; Ben Sprangers; Sabine Fevery; Omer Rutgeerts; Caroline Lenaerts; Louis Boon; Mark Waer; An D Billiau
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

2.  Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.

Authors:  Amir A Toor; Roy T Sabo; Harold M Chung; Catherine Roberts; Rose H Manjili; Shiyu Song; David C Williams; Wendy Edmiston; Mandy L Gatesman; Richard W Edwards; Andrea Ferreira-Gonzalez; William B Clark; Michael C Neale; John M McCarty; Masoud H Manjili
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

3.  Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.

Authors:  Carol D Jones; Sally Arai; Robert Lowsky; Dolly B Tyan; James L Zehnder; David B Miklos
Journal:  Br J Haematol       Date:  2010-06-07       Impact factor: 6.998

4.  Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients.

Authors:  R Oostvogels; E Kneppers; M C Minnema; R C Doorn; L E Franssen; T Aarts; M E Emmelot; E Spierings; I Slaper-Cortenbach; K Westinga; E Goulmy; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2016-11-14       Impact factor: 5.483

Review 5.  Minor histocompatibility Ags: identification strategies, clinical results and translational perspectives.

Authors:  R Oostvogels; H M Lokhorst; T Mutis
Journal:  Bone Marrow Transplant       Date:  2015-10-26       Impact factor: 5.483

Review 6.  The role of dendritic cells in graft-versus-tumor effect.

Authors:  Tomomi Toubai; Nathan Mathewson; Pavan Reddy
Journal:  Front Immunol       Date:  2014-02-21       Impact factor: 7.561

Review 7.  Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?

Authors:  Maud Plantinga; Colin de Haar; Stefan Nierkens; Jaap Jan Boelens
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

8.  Prolonged Survival of Subcutaneous Allogeneic Islet Graft by Donor Chimerism without Immunosuppressive Treatment.

Authors:  Brend Ray-Sea Hsu; Shin-Huei Fu; Aline Yen Ling Wang
Journal:  Int J Endocrinol       Date:  2017-06-21       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.